Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer
Lists
Only you see this
Abstract
Patients with locally advanced non-small cell lung cancer may tolerate 60mg/m(2) docetaxel and 60mg/m(2) cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.
BibTeX
@inproceedings{li2011phase,
author = {You‐Quan Li and Anhui Shi and Fuhai Li and Rong Yu and Guangying Zhu},
title = {{Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer}},
booktitle = {Chinese},
year = {2011},
doi = {10.1007/s11670-011-0129-9},
}Loading related content...